The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s autoimmune treatment market report forecasts the autoimmune treatment market size to grow to $10.98 Billion by 2027, with a CAGR (compound annual growth rate) of more than 12%.

Learn More On The Autoimmune Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Autoimmune Treatment Market Size Forecast
The global autoimmune treatment market is expected to grow from $6.08 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The autoimmune treatment market size is expected to grow to $10.98 billion in 2027 at a CAGR of 12.5%.

North America held the largest autoimmune treatment market share.

Key Autoimmune Treatment Market Driver ­– Increase In Investments In Research And Development Of Drugs For Autoimmune Diseases
For instance, in January 2020, Kyverna Therapeutics, a US-based biotechnology and cell therapy company, raised $25 million series A funding from Vida Ventures and Westlake Village Bio Partners investors and entered into a strategic partnership with Gilead Sciences. This funding will be used to enhance Kyverna’s treatment strategy, which integrates advanced T cell engineering and synthetic biology technologies to inhibit and remove autoreactive immune cells, which are the source of inflammatory diseases. Therefore, the increasing investments in research and development of drugs drives the autoimmune treatment market growth.

Request for A Sample Of The Global Autoimmune Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

Key Autoimmune Treatment Market Trend – Technological Advancement
Major companies operating in the market are developing advanced technologies to sustain their position in the market. For instance, in January 2020, Predicta Med, an Israel-based healthcare company operating in the autoimmune treatment market, launched Predicta Med which helps in the identification of autoimmune disorders for early detection and intervention. The artificial intelligence technology and machine learning helps to greatly speed up a procedure that generally requires more than four years and at least four different doctors. Also, the accuracy rate increases to 84%, and it can also accurately detect lupus, multiple sclerosis, psoriatic arthritis, and rheumatoid arthritis. This unique platform offers healthcare professionals an AI-powered way of expediting the diagnosis of autoimmune illnesses, which might improve provider efficiency, increase the efficacy of treatment, and improve patient care.

Autoimmune Treatment Market Segment
1) By Product: Consumables and Assay Kits, Instruments, Services
2) By Service Type: Consultation and Diagnosis, Therapy and monitoring, Drug development
3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases
4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs, Interferons, Other Drug Class
5) By End User: Clinical Laboratories, Hospitals, Other End Users

Autoimmune Treatment Market Major Players and Strategies
Major players in the autoimmune treatment market are Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, AstraZeneca Plc, Bristol-Myers Squibb Co., Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK plc, and Genentech Inc.

In October 2020, Johnson & Johnson, a US-based pharmaceutical industry company, acquired Momenta Pharmaceuticals, Inc. for an amount of $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to expand their leadership in immune-mediated diseases and drive further growth in the development of autoantibody-driven disorders. Momenta Pharmaceuticals, Inc. is a US-based biotechnology company operating in the autoimmune treatment market.

The Autoimmune Treatment Global Market Report 2023 covers regional data on autoimmune treatment market size, autoimmune treatment market trends and drivers, opportunities, strategies, and autoimmune treatment market competitor analysis. The countries covered in the autoimmune treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Autoimmune treatment refers to the management and care of a patient for the purpose of combating an autoimmune disease or disorder. This is a type of condition in which one’s immune system starts attacking its own body cells. The autoimmune treatment is used to treat autoimmune diseases.

View More Reports Related To The Autoimmune Treatment Market –
Autoimmune Disease Diagnosis Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023
Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: